180 related articles for article (PubMed ID: 35345553)
1. LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.
Cheng Y; Tang R; Li X; Wang B; Cheng Y; Xiao S; Sun P; Yu W; Li C; Lin X; Zhu Y
J Hepatocell Carcinoma; 2022; 9():203-220. PubMed ID: 35345553
[TBL] [Abstract][Full Text] [Related]
2. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma.
Liu F; Hou W; Liang J; Zhu L; Luo C
J Cancer; 2021; 12(13):4039-4048. PubMed ID: 34093808
[TBL] [Abstract][Full Text] [Related]
3.
Wang L; Yan K; He X; Zhu H; Song J; Chen S; Cai S; Zhao Y; Wang L
J Cancer; 2021; 12(1):217-223. PubMed ID: 33391418
[No Abstract] [Full Text] [Related]
4. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.
Yang S; Cheng Y; Wang X; Wei P; Wang H; Tan S
Front Genet; 2021; 12():777931. PubMed ID: 34899862
[No Abstract] [Full Text] [Related]
5. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
[TBL] [Abstract][Full Text] [Related]
6. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma.
Wang M; Xiong Z
Int J Gen Med; 2021; 14():6343-6358. PubMed ID: 34629898
[TBL] [Abstract][Full Text] [Related]
7. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.
Liu B; Dong Z; Lu Y; Ma J; Ma Z; Wang H
Evid Based Complement Alternat Med; 2022; 2022():3478861. PubMed ID: 36034941
[TBL] [Abstract][Full Text] [Related]
9. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.
Yu G; Mu H; Fang F; Zhou H; Li H; Wu Q; Xiong Q; Cui Y
Medicine (Baltimore); 2022 Jul; 101(26):e29763. PubMed ID: 35777027
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
[TBL] [Abstract][Full Text] [Related]
11. Exploration of Key Genes Combining with Immune Infiltration Level and Tumor Mutational Burden in Hepatocellular Carcinoma.
Chen J; Zhang L; Lu CH; Xu CZ
Comb Chem High Throughput Screen; 2024 Jan; ():. PubMed ID: 38213141
[TBL] [Abstract][Full Text] [Related]
12.
Brown LC; Tucker MD; Sedhom R; Schwartz EB; Zhu J; Kao C; Labriola MK; Gupta RT; Marin D; Wu Y; Gupta S; Zhang T; Harrison MR; George DJ; Alva A; Antonarakis ES; Armstrong AJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653800
[TBL] [Abstract][Full Text] [Related]
13. Association of
Chen H; Chong W; Wu Q; Yao Y; Mao M; Wang X
Front Immunol; 2019; 10():1113. PubMed ID: 31164891
[No Abstract] [Full Text] [Related]
14. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
15. DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Song Y; Huang J; Liang D; Hu Y; Mao B; Li Q; Sun H; Yang Y; Zhang J; Zhang H; Chen H; Liu H; Zhang S
Front Oncol; 2020; 10():549777. PubMed ID: 33680909
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
17. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
18. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
19. Correlation between
Hu S; Zhao X; Qian F; Jin C; Hou K
Comput Math Methods Med; 2021; 2021():1522250. PubMed ID: 34603481
[TBL] [Abstract][Full Text] [Related]
20. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
